Literature DB >> 19876936

In vitro-in vivo correlation for nevirapine extended release tablets.

Sreeraj Macha1, Chan-Loi Yong, Todd Darrington, Mark S Davis, Thomas R MacGregor, Mark Castles, Steven L Krill.   

Abstract

An in vitro-in vivo correlation (IVIVC) for four nevirapine extended release tablets with varying polymer contents was developed. The pharmacokinetics of extended release formulations were assessed in a parallel group study with healthy volunteers and compared with corresponding in vitro dissolution data obtained using a USP apparatus type 1. In vitro samples were analysed using HPLC with UV detection and in vivo samples were analysed using a HPLC-MS/MS assay; the IVIVC analyses comparing the two results were performed using WinNonlin. A Double Weibull model optimally fits the in vitro data. A unit impulse response (UIR) was assessed using the fastest ER formulation as a reference. The deconvolution of the in vivo concentration time data was performed using the UIR to estimate an in vivo drug release profile. A linear model with a time-scaling factor clarified the relationship between in vitro and in vivo data. The predictability of the final model was consistent based on internal validation. Average percent prediction errors for pharmacokinetic parameters were <10% and individual values for all formulations were <15%. Therefore, a Level A IVIVC was developed and validated for nevirapine extended release formulations providing robust predictions of in vivo profiles based on in vitro dissolution profiles. Copyright 2009 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19876936     DOI: 10.1002/bdd.691

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  7 in total

1.  "Forgiving" a missed daily dose.

Authors:  Thomas R Macgregor
Journal:  AIDS Res Hum Retroviruses       Date:  2011-02-22       Impact factor: 2.205

2.  Development, Internal and External Validation of Naproxen Sodium Sustained Release Formulation: an Level A In Vitro-In Vivo Correlation.

Authors:  Ramesh Narayanasamy; Ramakrishna Shabaraya
Journal:  Turk J Pharm Sci       Date:  2017-08-15

3.  Twice-daily versus once-daily antiretroviral therapy and coformulation strategies in HIV-infected adults: benefits, risks, or burden?

Authors:  Jean B Nachega; Bernd Rosenkranz; Paul A Pham
Journal:  Patient Prefer Adherence       Date:  2011-12-28       Impact factor: 2.711

4.  Formulation, optimization, and evaluation of self-emulsifying drug delivery systems of nevirapine.

Authors:  Ramprasad Chintalapudi; T E G K Murthy; K Rajya Lakshmi; G Ganesh Manohar
Journal:  Int J Pharm Investig       Date:  2015 Oct-Dec

5.  Efficacy and safety of switching from nevirapine immediate-release twice daily to nevirapine extended-release once daily in virologically suppressed HIV-infected patients: a retrospective cohort study in Taiwan.

Authors:  Chun-Yuan Lee; Hui-Min Chang; Calvin M Kunin; Susan Shin-Jung Lee; Yao-Shen Chen; Hung-Chin Tsai
Journal:  BMC Infect Dis       Date:  2017-04-11       Impact factor: 3.090

6.  Pharmacological and clinical evidence of nevirapine immediate- and extended-release formulations.

Authors:  Javier Ena; Concepción Amador; Conxa Benito; Francisco Pasquau
Journal:  HIV AIDS (Auckl)       Date:  2012-11-15

7.  Development of in vitro - in vivo correlations for newly optimized Nimesulide formulations.

Authors:  Muhammad Hanif; Muhammad Harris Shoaib; Rabia Ismail Yousuf; Farya Zafar
Journal:  PLoS One       Date:  2018-08-31       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.